The use of COVID-19 convalescent plasma (CCP) as a therapeutic option, despite its ups and downs, has shown the European Union’s renewed interest in plasma-derived medicinal products (PDMPs).
Last spring, plasmapheresis was considered one of the most promising treatments for COVID-illness. Plasma is one of the blood components, together with red blood cells and platelets, that can be transfused to other patients and can also be used for manufacturing PDMP.
The principle behind this potential therapeutic option is simple: plasma obtained from the blood of healthy people who overcame the disease has specific antibodies that could be valuable in treating other COVID-19 patients.
Lab Leak: A Scientific Debate Mired in Politics — and Unresolved medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Antibody Mediated Prevention (AMP) trials data published by the
New England Journal of Medicine
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
Public Relations Pacific LLC
E-Mail
SEATTLE - (EMBARGOED UNTIL MARCH 17, 2021, AT 5 P.M. ET) - The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb. As the resistant strains constituted nearly 70% of the circulating strains in these regions, there was no difference noted between the VRC01 arms and placebo arm in terms of overall prevention of HIV acquisition. The sensitivity to bNAbs was assessed by a laborat
Kanta Subbarao Professor, The Peter Doherty Institute for Infection and Immunity
We face a range of possible scenarios. At the most optimistic end of the spectrum, new vaccines will protect against all current and future variants of concern. At the other extreme, we’ll see the frequent emergence and spread of new variants, against which existing vaccines will have limited effect.
It’s likely we’ll land somewhere in the middle.
Notably, although new variants do threaten the effectiveness of COVID-19 vaccines, decades of experience updating influenza vaccines can inform our global response.
Evolving variants
We’re still learning about how new viral variants affect vaccine effectiveness.
COVID-19 outbreak declared at Chatham-Kent place of worship norfolkandtillsonburgnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from norfolkandtillsonburgnews.com Daily Mail and Mail on Sunday newspapers.